Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Distributes Ayushman cards to several beneficiaries
The product will be manufactured at Lupin’s Nagpur facility in India
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated